Want to see IMNM full AI Analyst Report?
IMNM Stock Chart & Stats
$24.63
-$0.28(-2.60%)
At close: 4:00 PM EST
$24.63
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$7.96 - $27.65
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.30M
Market Cap
$2.43B
Enterprise Value$1.19B
Total Cash (Recent Filing)$582.69M
Total Debt (Recent Filing)$3.69M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 19, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding113,250,400
10 Day Avg. Volume1,479,723
30 Day Avg. Volume1,297,579
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue296.98
Enterprise Value/Gross Profit-25.56
Enterprise Value/Ebitda-5.38
Forecast
1Y Price Target
$35.50Price Target Upside44.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.14
Revenue Forecast (FY)$2.51M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong SolvencyExtremely low leverage meaningfully reduces near-term solvency and refinancing risk for a clinical-stage biotech. This balance sheet flexibility supports continued R&D and clinical programs without immediate debt-servicing pressure, giving management time to advance pipeline or secure partnership funding.
Proprietary Antibody Discovery PlatformA dedicated antibody discovery platform is a structural competitive asset: it can generate multiple preclinical candidates, enable efficient target identification, and underpin collaborations or licensing. This platform-driven model can create recurring value beyond single programs and supports durable pipeline expansion.
Collaborations / Licensing Revenue ModelHaving collaboration and licensing as core revenue sources diversifies funding beyond product sales. Milestones, upfronts and R&D funding from partners can partially offset clinical spend, lowering sole dependence on equity raises and supporting program advancement if partnerships are sustained or expanded.
Bears Say
High Operating Cash BurnSustained, large negative operating and free cash flows create persistent funding needs and elevate dilution or financing risk. For a clinical-stage company, this magnitude of burn pressures the timing of program advancement and forces reliance on capital markets or partner deals to maintain development cadence over the next several quarters.
Declining Revenue And Negative MarginsMaterial revenue decline combined with deep net losses and negative gross profit indicate the business lacks scale to cover R&D and SG&A. Persistently deteriorating top-line and margins undermine self-funding prospects and make long-term sustainability contingent on securing new partnerships or substantial external capital.
Equity Erosion / Dilution RiskDeclining shareholders' equity and negative returns on equity reflect continued losses and likely past financing activity. Ongoing cash burn combined with shrinking equity increases the probability of future equity issuance, diluting existing holders and complicating long-term shareholder value recovery if revenue and profitability do not improve.
Immunome News
IMNM FAQ
What was Immunome, Inc.’s price range in the past 12 months?
Immunome, Inc. lowest stock price was $7.96 and its highest was $27.65 in the past 12 months.
What is Immunome, Inc.’s market cap?
Immunome, Inc.’s market cap is $2.43B.
When is Immunome, Inc.’s upcoming earnings report date?
Immunome, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 48 days.
How were Immunome, Inc.’s earnings last quarter?
Immunome, Inc. released its earnings results on May 12, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.556 by $0.076.
Is Immunome, Inc. overvalued?
According to Wall Street analysts Immunome, Inc.’s price is currently Undervalued.
Does Immunome, Inc. pay dividends?
Immunome, Inc. does not currently pay dividends.
What is Immunome, Inc.’s EPS estimate?
Immunome, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Immunome, Inc. have?
Immunome, Inc. has 113,250,400 shares outstanding.
What happened to Immunome, Inc.’s price movement after its last earnings report?
Immunome, Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.556. Following the earnings report the stock price went down -2.16%.
Which hedge fund is a major shareholder of Immunome, Inc.?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.50 (44.13% Upside)
$35.50 (44.13% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 490.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $604.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
127.84%
12-Months-Change
Fundamentals
Return on Equity
-51.15%
Trailing 12-Months
Asset Growth
80.86%
Trailing 12-Months
Company Description
Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
IMNM Stock 12 Month Forecast
Average Price Target
$35.50
▲(44.13% Upside)
Technical Analysis
Ownership Overview
4.75% Insiders
36.50% Mutual Funds
42.23% Other Institutional Investors
3.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---